Advertise on podcast: GTSC Podcast

In this GTSC podcast, Dr. Elliot Servais joins Dr. Jessica Donington and Dr. Biniam Kidane to explore the complex judgment involved in assessing resectability in the era of perioperative chemoimmunotherapy. The discussion highlights the critical distinctions among technical, oncologic, and physiologic resectability, as well as the essential role of surgeons and the multidisciplinary team in guiding treatment decisions.

In this episode of the General Thoracic Surgical Podcast, Dr. Linda Martin and Dr. Rishi Reddy explore the rapidly evolving landscape of lung nodule localization—a critical topic as thoracic surgeons increasingly encounter smaller, non-palpable nodules due to expanded screening and imaging practices. The conversation covers the full spectrum of localization techniques—from traditional wire and dye marking to advanced robotic bronchoscopy, ICG (indocyanine green) fluorescence, and molecular imaging agents such as CYTALUX® (pafolacianine) injection. The discussion highlights workflow integration, patient safety, cost considerations, and the implications of emerging bronchoscopic ablation and molecular-targeted visualization technologies on the future of thoracic oncology. This episode is proudly sponsored by On Target Laboratories.

In this podcast, Drs. Linda Martin (UVA) and Dennis Wigle (Mayo Clinic Rochester, MN) discuss key updates in the treatment of early stage surgically resectable non small cell lung cancer from the 2025 American Society of Clinical Oncology Annual Meeting. Topics include updated survival data from the CheckMate 816 trial of neoadjuvant nivolumab plus chemotherapy, the practice impact of PROSPECT lung accrual, and results from the NeoADAURA trial of neoadjuvant osimertinib. This episode was sponsored by BMS.

In this podcast, Drs. Linda Martin and Jessica Donington discuss the evolving approach to treating N2 disease in stage 3 lung cancer, emphasizing the shift from therapeutic nihilism to more aggressive surgical strategies. They highlight the success of combining chemotherapy, immunotherapy, and surgery, which has led to improved outcomes, especially in patients with multi-station N2 disease, while noting the importance of rethinking traditional treatment paradigms and focusing on systemic control rather than local clearance alone.

In this episode of the GTSC podcast, Dr. Dennis Wigle (Mayo Clinic) and Dr. Linda Martin (UVA) review the recently published ALINA trial of adjuvant alectinib for resected ALK-positive NSCLC. We also review recently presented lung and esophageal cancer data from ASCO 2024, including ESOPEC, CheckMate 816 and 77T, AEGEAN, and the LU002 trial results for oligometastatic lung cancer. This podcast is sponsored by Genentech.

Dennis Wigle and Linda Martin from Mayo Clinic and University of Virginia, respectively, discuss recent trials from the meeting of the European Society for Medical Oncology (ESMO), particularly highlighting the ALINA trial focusing on adjuvant treatments for resected non small cell lung cancers with impressive differences in outcomes between Alectinib and platinum-based chemotherapy. In addition, they provide a review of multiple perioperative immunotherapy trials from 2023 and share their hopes for the field in 2024. This podcast is sponsored by Genentech.

Drs. Linda Martin (University of Virginia) and Dennis Wigle (Mayo Clinic) review recent clinical trial publications on sublobar resection for early stage lung cancer, and the use of immunotherapy before surgery for later stage (locally advanced) lung cancer. We review the studies involved and provide perspective on the results and what they mean for patient care. This podcast is sponsored by Genentech.